.Pharmacolibrary.Drugs.ATC.L.L01EX23 .Pharmacolibrary.Drugs.ATC.L.L01EX23| name: | Pralsetinib | |
| ATC code: | L01EX23 | route: | oral |
| compartments: | 2 | |
| dosage: | 400 | mg |
| volume of distribution: | 881 | L |
| clearance: | 21.9 | L/h |
| other parameters in model implementation | ||
Pralsetinib is an orally administered, selective RET receptor tyrosine kinase inhibitor used for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant or RET fusion-positive thyroid cancers. It is approved by the FDA and EMA for these indications.
Pharmacokinetic parameters reported for adult patients with advanced solid tumors, based on population PK analysis.